Seattle, WA -- (SBWIRE) -- 11/08/2019 -- Pulmonary hypertension or PAH is type of blood pressure that affects the arteries in lungs and right side of the heart. In this condition, blood pressure rises in the pulmonary artery, vein, or capillaries (collectively known as lung vasculature), which might lead to shortness of breath, fainting, leg swelling, and dizziness. Pulmonary hypertension may be a relentless disease with a noticeable reduction in exercise tolerance. PAH also indicates that the patient has high blood pressure in arteries that carry blood from the heart to the lungs. This high blood pressure either makes arteries in lungs thin or get blocked. In simple words, it means that the heart works harder to pump blood. It may lead to weakening of the heart muscles after a certain period of time. Ultimately, pulmonary arterial hypertension may cause heart failure.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/203

Based on the reports gathered from a variety of sources, including the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO), the global prevalence of pulmonary arterial hypertension is projected to be 100,000 – 200,000, that is about 15 - 50 patients per million of the population. Even though, the treatment available for pulmonary arterial hypertension is rather limited, various treatment options are available to decrease symptoms, slow down disease progression, and improve the quality of life. Endothelin receptor antagonists or ERAs, phosphodiesterase-5 (PDE-5) inhibitors and Prostacyclin and prostacyclin analogs are some of the widely prescribed drug classes used for treatment of the disease. Lately, a new drug class known as the soluble guanylate cyclase or sGC stimulators has been recognized to be effective in treating people with PAH.

On the contrary, the expiry of patents of major pulmonary arterial hypertension drugs such as Letairis, Tracleer, Tyvaso, and Adcirca is expected to hinder growth of the market in the near future, as the generic versions of these drugs will be sold at 70% to 80% lower prices than that of the present branded drugs. Various breakthrough therapies for treatment of pulmonary arterial hypertension is projected to be a growth factor for the PAH treatment drug manufacturers, since the available drugs for the same are not sufficient to meet the patient's needs. These factors will fuel growth of the global pulmonary arterial hypertension (PAH) market during the forecast period.

Global Pulmonary Arterial Hypertension (PAH) Market Taxonomy

On the basis of drug class, the global pulmonary arterial hypertension (PAH) market is classified into:
? ERA
? Prostacyclin and Prostacyclin Analogs
? sGC Stimulators
? PDE-5 Dipsticks
On the basis of application, the global pulmonary arterial hypertension (PAH) market is classified into:
? Hospitals
? Clinics
? Others
On the basis of drug lass, ERA segment held the dominant positions in the global pulmonary arterial hypertension (PAH) market. Moreover, the prostacyclin and prostacyclin analogs segment is projected to expand at the highest CAGR over the forecast period, owing to the authorization of Orenitram (treprostinil extended release tablet) in 2013 and the expected endorsement of Uptravi (selexipag) in 2016.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/203

Market Dynamics

Growing prevalence of cardiac diseases to drive growth of the global pulmonary arterial hypertension (PAH) market

Sedentary lifestyles, growing consumption of fast food, and lack of exercise, the global numbers for the patients with cardiac diseases is expected to increase significantly over the forecast period thereby, increasing the susceptibility of pulmonary arterial hypertension among the global population. Thus, these factors are expected to drive growth of the global pulmonary arterial hypertension (PAH) market during the forecast period.

Regional Insights

Among regions, North America accounted for the largest market share of the global pulmonary arterial hypertension (PAH) treatment market, followed by Europe. These regional market are projected to witness considerable growth in the forecast period, owing to the freshly approved PAH medicines in the market and high prevalence of heart diseases.

Competitive Landscape

Key players operating in the pulmonary arterial hypertension global pulmonary arterial hypertension (PAH) market are Actelion Pharmaceuticals, Ltd., Gilead Sciences, Inc., United Therapeutics Corporation, Bayer HealthCare, Pfizer, Inc., Novartis International AG, and GlaxoSmithKline plc.

Key Developments

Key institutes and organizations are involved in various strategies such as research and development, in order to produce novel products for pulmonary hypertension. For instance, in August 2019, researchers from the Boston University and UT Southwestern Medical Center, William P. Clements Jr. University Hospital conducted Phase 2 study to assess the efficacy, safety, and tolerability of immediate-release orally administered ralinepag, a selective, non-prostanoid prostacyclin receptor (IP) agonist for the treatment of pulmonary arterial hypertension (PAH). The research published in the European Respiratory Journal found that ralinepag reduces pulmonary vascular resistance in pulmonary arterial hypertension.

Similarly, in August 2019, Altavant Sciences, a clinical-stage biopharmaceutical company, announced that it has dosed the first patient in a Phase 2a study to assess the efficacy of rodatristat ethyl, a tryptophan hydroxylase inhibitor designed to reduce the body's peripheral production of serotonin, in patients with pulmonary arterial hypertension (PAH).

In August 2019, researchers from University of South China and other Chinese institutes determined the functions of Eukaryotic initiation factor 2? (eIF2?) and autophagy in the vascular remodeling of the monocrotaline-induced PAH rats and to clarified the correlation between eIF2? and autophagy. In the research published in Dovepress, the team found that eIF2? promotes the proliferation of pulmonary artery smooth muscle cells and vascular remodeling in monocrotaline-induced PAH rats through accelerating autophagy pathway.

For Complete Information: https://www.coherentmarketinsights.com/ongoing-insight/pulmonary-arterial-hypertension-pah-market-203

About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.